Treatment of Stroke Recurrence in CAA with Tranexamic Acid (ACTRN12624001477516)

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Geoffrey Cloud

Key inclusion data

Inclusion Criteria: Probable diagnosis of CAA by modified Boston Criteria 2.0 Recent symptomatic intracranial bleeding (ICH, cSAH, or both) within 6 months prior to randomization. (Refer to Table 2); At least 2 or more?of the following strictly lobar haemorrhagic lesions on T2*-weighted MRI, in any combination: ICH, CMB, cSS/cSAH foci; Able to have MRI at baseline and 6-month follow-up. Exclusion Criteria: Unable to have MRI or any contraindications to MRI; Renal impairment (eGFR < 30 mls/min/1.73m2); Epilepsy; Known fibrinolytic condition; History of unprovoked venous thromboembolism (VTE) (e.g. deep vein thrombosis (DVT), pulmonary embolism PE), Cerebral Venous Sinus thrombosis (CVST)) within 12 months of randomisation; History of haematuria or renal parenchymal disease; Myocardial infarction (MI) within 12 months of randomisation; Functionally dependent (score of >3 on the modified Rankin scale).